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and Sure Death, an itinerant history of epidemic disease
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Numerical methods to assess the effects of medical
interventions were introduced during the 18th cen-
tury1 and became increasingly sophisticated between
the mid-19th and mid-20th centuries. The transition
occurred from reports of single cases and case series,
controlled, in essence, by unquantified past experience;
through quantitative comparisons with historical
controls and concurrent controls subject to selection
biases; to the adoption of alternation to ensure that
like would be compared with like, sometimes using
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blinding to reduce observer biases; with increasing
recognition of the need to study sufficiently large
numbers of patients (see www.jameslindlibrary.org).
To illustrate these developments in research meth-
odology over this period, we have chosen to look at
important therapeutic innovations, and how they
were evaluated. Treatment of diphtheria is such a
case. Until the end of the 19th century, diphtheria was
a major killer, mostly of children, but also of adults.
However, patients with diphtheria were among the
first to benefit from the development and evaluation
of specific treatments for infectious diseases,2 and
deaths from the disease fell dramatically in many
countries.3
The history of diphtheria treatment is characterized by
three inventions—tracheotomy, intubation and serum
therapy—introduced between the 1840s and the
1890s. The importance of serum therapy was singled
out for award of the first Nobel prize in Physiology or
Medicine (1901), implying that the beneficial effects
of the therapy had been widely accepted. However,
uncertainty resulting from the fluctuating severity of
diphtheria over time and debate about which inter-
ventions actually influenced outcomes meant that the
disease provided fertile ground for developing meth-
ods for evaluating the effects of new treatments.
Attention has previously focused upon Johannes
Fibiger’s 1898 report of the use of serum in patients
admitted on alternate days to his hospital in
Copenhagen,4 using the experience of patients
admitted on other days for comparison. Drawing on
studies reported by French, German, American,
Danish, Dutch and British researchers, the current
article will situate Fibiger’s study as a key represen-
tative in a series of assessments of therapeutic efficacy
during this critical era, thus providing an example of
the evaluation methods practised and internationally
considered valuable in that era.
Case reports and case series
assessing the effects of
tracheotomy and tracheal
intubation for laryngeal
obstruction caused by diphtheria
Diphtheria most often leads to death if left untreated
because of obstruction of the upper airways by an
adherent membrane. Pierre-Fide`le Bretonneau—who
introduced the term diphtheria in 1817—is usually
credited with having documented the first successful
use of tracheotomy to relieve laryngeal obstruction
caused by the disease. After two unsuccessful oper-
ations in 1818 and 1820, his third (done in 1825) was
successful.5 Bretonneau’s pupil, Emile Trousseau,
also had two failed operations (in 1826 and 1828)
before succeeding in 1831.6,7 In 1855, Trousseau re-
ported on the fate of 216 children in whom he had
used tracheotomy at the Hoˆpital des Enfants-Malades
in Paris.8 Of them, 47 children (22%) had survived, a
result that he rated as remarkable, given the dire nat-
ural history of laryngeal obstruction caused by
diphtheria:
This result is considerable if one thinks about the
social conditions of the children brought here,
about the deplorable treatment given by the
midwives (. . .), if one thinks about the disastrous
conditions of the hospital itself, where children are
placed in the middle of the most serious and most
different contagions: so that very often, at a time
when everything seems to work well after trache-
otomy, scarlet fever, measles, cowpox, whooping-
cough introduce formidable complications.8
Tracheal intubation as an alternative to tracheot-
omy, an ancient and forgotten practice, was revived
in France in 1855 by a surgeon in Lyon, J-F Reybard
(1795–1863), who used silver cannulae to perforate
the diphtheritic membrane. His method was pre-
sented to the Academy of Medicine as a substitute
for tracheotomy, to the satisfaction of opponents of
the latter.9 Intubation was later presented to academ-
icians in greater detail by Eugene Bouchut (1818–91)
as a method to replace tracheotomy, provided a new
type of cannula was used:10,11
One could replace tracheotomy, a difficult and
dangerous operation associated with a mortality
of 80 to 90% and sometimes more, with a new
operation, bloodless, devoid of all danger, [and]
as easy to imagine as to accomplish: this is intu-
bation of the trachea.10
Bouchut’s report was discussed in November 1858 at
the Academy of Medicine and Trousseau was asked to
examine and report on the method. As tracheal intub-
ation challenged tracheotomy,7 Trousseau’s long report
dismissed the former and promoted the latter, draw-
ing attention to the insufficient number of cases (only
seven) treated by intubation.12 Despite continued
criticism of tracheotomy, the operation remained dom-
inant, although tracheal intubation remained on the
list of hospital practices. When Bouchut was ap-
pointed as chief physician at the Hoˆpital des
Enfants-Malades in Paris, he placed intubation on
the top of his list of treatments for diphtheria, fol-
lowed by tonsillectomy (which he described in great
detail). Tracheotomy was relegated to be used only
after other techniques had failed.13
In 1887, an American paediatrician, Joseph
O’Dwyer, using an improved technique of tracheal in-
tubation, published a detailed account of 50 patients
with croup treated by intubation, 12 (24%) of whom
survived.14 Tracheal intubation was widely accepted
in the USA and rapidly superseded tracheotomy as a
standard procedure. Although guidelines for perform-
ing intubation were widely publicized in France,7,15,16
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the procedure was not readily accepted in Europe,
both because of the influence of prominent phys-
icians, and because of the perceived risks associated
with intubation through inflamed tissues. Intubation
became a common practice in Europe only after
serum therapy had been introduced, with consequent
reduction of local inflammation and the risks asso-
ciated with it.7
In attempts to kill the bacteria, measures used in
the late 19th century included disinfection of the
upper respiratory tract with glycerine and salicylic
acid and washing with calomel or with boric and
phenolic acid added to water.17–19 However, the pur-
ported effects of these interventions were not quanti-
fied, but supported by statements such as ‘the
membranes were more easily dislodged after such
washings’.16
Use of historical and concurrent
controls to assess the effects
of measures to prevent
cross-infection with diphtheria
and other organisms in hospital
Although tracheotomy and intubation could be lifesav-
ing, patient fatality rate remained high throughout the
19th century. At the end of the century, about half of
the children admitted to hospital with diphtheria
died,20 the most seriously affected patients often
being infected with streptococci or staphylococci as
well.18 Joseph Grancher (1843–1907), one of the phys-
icians in charge of the Infectious Diseases Service at
the Hoˆpital des Enfants-Malades, had established that
diphtheria was not transmitted by circulating air but
rather through person-to-person contacts, or contacts
with the personal belongings of diphtheria patients.
To reduce such super-infection of diphtheria patients
with other micro-organisms, as well as to reduce the
spread of diphtheritic infection to uninfected children
in the hospital, Grancher established a set of guide-
lines based on the principles of asepsis and isolation
techniques that had been adopted in departments of
surgery and obstetrics.22 Rather than proposing a spe-
cialist diphtheria hospital, therefore, Grancher’s report
to the executive ministry responsible for public
health (report read and approved at the Comite´ consul-
tatif d’hygie`ne de France on November 10, 1890) recom-
mended the implementation of rigorous hygiene
and asepsis in existing hospitals, as well as meas-
ures to limit cross-infection during the transport of
patients by the recently established ambulance
service.23
Accordingly, Grancher reorganized the wards for
which he was responsible by surrounding each bed
with a 1.2 -m high wire gauze screen to minimize
movement between beds and by providing each
semi-isolated ‘cubicle’ thus created with individual
equipment, sterilized every other day, for food and
care. The staff were required to obey very strict asep-
sis rules when moving from one cubicle to another,
washing their hands with mercury sublimate
and changing their overalls. Bed clothes were steri-
lized after each patient had been discharged from
hospital.
Grancher claimed that improvements were evident
as soon as these new measures had been intro-
duced.23 In his wards, there had been 19–35 patients
with diphtheritic cross-infections out of an average of
500–600 patients per year in the years before the cu-
bicles had been introduced (3–6%) compared to only
one patient (with a dubious diagnosis) out of 575
patients the year following the introduction of the
new procedures. Furthermore, in other wards (for
measles, surgery and internal medicine) in the
Hoˆpital des Enfants-Malades, which had not been
equipped with cubicles, there had been a total of
153 patients of diphtheritic cross-infections (3%)
of about 4000–5000 patients (an estimate based on
the average number of patients in those wards in
1887 and 1888). Grancher gives as an example of
the frequency of cross-infections, the fact that there
had been three diphtheritic cross-infections (6%)
during the first 6 months of 1889 out of a total of
47 patients admitted to Husson ward (for patients
with chronic diseases), which had not been equipped
with cubicles. In contrast with the reduction in diph-
theritic cross-infections, no decrease in the spread
of measles, which was anyway assumed to be a
more transmissable infection, was observed within
Grancher’s wards.
The first case series describing
serum therapy for diphtheria
Diphtheria’s effects are caused by a toxin produced by
the bacterium Corynebacterium diphtheriae. This toxin
produces not only diphtheria’s effects in the upper re-
spiratory tract, but also later complications, including
myocarditis and peripheral neuropathy. These compli-
cations and superinfection with other bacterial patho-
gens (streptococci, in particular), contribute to the
serious morbidity and mortality associated with the
disease.
In the early 1890s, in Berlin, Emil von Behring and
Shibasabura Kitasato developed a serum from a
hyper-immune horse, which seemed to confer passive
immunity on patients with diphtheria. Experience
with this serum was first reported in a paper pub-
lished in 1893.24 The authors were cautious in
presenting their findings, noting that ‘The innocuous-
ness of a treatment . . . is one of the preconditions for
justifying a recommendation that it be introduced for
therapy in humans. The second, even more important
precondition, is evidence of the value foreseen by
using it’.
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They provided a detailed account of their approach
(Box 1). They presented their results cautiously,
emphasizing that all 30 children treated with serum
had had diphtheria confirmed bacteriologically and
their promising results called for replication on a
large-scale:
So far in the past months 30 cases have been trea-
ted with [our] normal serum (or with the equiva-
lent dog curative diphtheria serum of Medical
Officer Wernicke): 14 in Berlin, 3 of whom were
in Counsellor Henoch’s children’s department; in
all of them the diagnosis ‘diphtheria’ has been re-
liably established, in particular, in our Institute,
every case in which diphtheria bacilli could not
be detected bacteriologically was excluded. Out of
these 30 cases, 6 died and 24 have been cured; this
is a mortality rate of 20%.
These numbers are still much too small to allow
a conclusive judgement about serum therapy: but
they are nevertheless encouraging and [they]
prompt continuation of serum treatment on an
extended scale. Only when we have statistics on
hundreds and thousands of diphtheria patients
treated with serum will it be the time to deduce
final conclusions about the effectiveness of the
curative diphtheria serum against this so murder-
ous disease, particularly in childhood.
Historical and concurrent controls
to assess the effects of serum
treatment for diphtheria
Grancher’s Infectious Disease department at the
Hoˆpital des Enfants-Malades in Paris was the site of
the first controlled evaluation of the effects of serum
treatment for diphtheria.20 Between February 1 and
July 24, 1894 (thus including winter and summer
months), Emile Roux, Louis Martin and Auguste
Chaillou collected detailed information on 448 chil-
dren admitted to the diphtheria service. In addition
to information about the diphtheritic infection itself,
such as duration of the illness, data were collected
on age, pulse, breathing rhythm and albuminuria,
and information on any complications—from mea-
sles, bronchopneumonia, scarlet fever or other
co-morbidities. Soon after admission to the hospital,
20 children died but 428 received hyper-immune
horse serum in doses ranging from 20 to 125 cc, de-
pending on the severity of the illness and the presence
of associated pathologies.
Of the 448 children admitted, 109 died—a fatality
of 24.5%. This compared very favourably not only to
a rate of about 50% in the same hospital during
the 4 years 1891–93, but also to a fatality of 60%
in the Hoˆpital Trousseau, where serum had not been
used.
Roux, Martin and Chaillou distinguished diphtherit-
ic sore throat (angine diphte´rique) from laryngeal diph-
theria (croup), the latter being defined by whether or
not tracheotomy had been used. They also stressed
the different degrees of seriousness, depending on
whether the diphtheritic croups were pure or asso-
ciated with other conditions (in cases associated
with staphylococcal and streptococcal infections fatal-
ity reached 63% and 80%, respectively). Further ana-
lyses of their crude statistics showed that, when
consideration was restricted to patients with diphther-
itic sore throat, more dramatic differences in favour of
the serum emerged—12% died compared to an aver-
age of 34% in previous years, and 32% at the Hoˆpital
Trousseau. Figures were also presented for the pa-
tients in whom tracheotomy had been used, among
whom 49% had died compared to an average of 73%
during previous years and 86% at the Hoˆpital
Trousseau.
Roux, Martin and Chaillou further refined their ana-
lyses of the 448 children in two ways. First, they
identified and removed from their analysis the 128
children in whom there was no bacteriological con-
firmation of infection with the diphtheria bacillus.
Second, they excluded the 20 children who had died
soon after arriving at the hospital and who had not
received serum. This left 300 patients with bacterio-
logically confirmed diphtheria who had received
serum. These patients experienced a case fatality of
26% compared to 50% among similar patients in
the same hospital over previous years.
Box 1 Extract from the report by Behring, Boer
and Kossel of their use of anti-diphtheritic serum
(Source: Behring et al.23)
‘We make our medicaments ourselves, we test them
ourselves, firstly, not in man, but in animals; we
determine ourselves the conditions in which they
are innocuous, and the limits within which this is
the case; we try out their influence on the course of
the human diseases produced in animals, using
Robert Koch’s methods and when we have deter-
mined a specifically curative effect, we take pains
to perfect these specific drugs until their applica-
tion in man also promises a totally specific effect;
only now will we ourselves assess the innocuous-
ness of these specific drugs in the clinical depart-
ment of the Institute for Infectious Diseases.
Observations in patients are not needed to establish
the specificity of these drugs; they are needed only
to confirm it. Next, decisions are required about
whether the new drug is already effective enough to
elicit unambiguous curative effects in patients.
And, when this has been established, we have fi-
nally to answer questions of dosage and the most
appropriate route of administration. Only when we
have accomplished all this do we dare to give our
remedy to those doctors who are not yet trained in
this kind of drug evaluation for them to test on
their own patients . . .’
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Finally, they compared the mortality among 120
children with ‘pure’ laryngeal diphtheria who had
received serum to the mortality among 96 similar
children admitted in 1891 and 1892. The case fatality
rates were 7.5 and 41%, respectively and the authors
provided plausible reasons for the deaths of the nine
infants who had died in spite of receiving the serum.
Serum treatment had also been associated with a
reduced use of tracheotomy.
Unsurprisingly, Emile Roux and his colleagues con-
cluded that this evidence supported their belief that,
as serum was the only new element that had been
introduced at the Hoˆpital des Enfants-Malades, the
beneficial changes had to be attributed to the treat-
ment.20 It is worth noting that Roux and his col-
leagues used the word ‘statistiques’, albeit without
presenting statistical analysis as such.21
In September 1894, Emile Roux presented these
findings to the International Congress of Hygiene, in
Budapest, and this marked the introduction of wide-
spread use of serum therapy in Europe.20,25,26 In the
course of the discussion, which accompanied the
report of Roux’s lecture, the author mentioned that
Hans Aronson of Berlin had reported comparable re-
sults concerning the treatment of diphtheria patients
with anti-diphtheria serum made in Germany.
Aronson mentioned a procedure for obtaining high-
titre serum (allegedly three times more efficient than
Behring’s serum), the use of which had resulted in a
decrease in case fatality rate from 40% to 15% among
bacteriologically confirmed diphtheritic patients26–28
(quoting Aronson).
The results obtained in Paris were reflected not only
in Berlin, but elsewhere. For example, an American
textbook29 published soon after the French and
German results had been reported concluded that
the value of anti-toxin serum had been established,
but, ‘so that readers may themselves to a certain
extent have a basis for forming their own opinions’,
statistics were presented showing trends in fatality
among patients admitted to the Willard Parker
Hospital for Contagious Diseases in New York, and
the Kaiser-und-Kaiserin Friedrich Augusta Hospital
in Berlin.30
Statistics were frequently used to assess the efficacy
of anti-streptococcal and anti-diphtheritic serotherapy
in Paris. In contrast, they were rarely used to assess
anti-venomous, anti-tetanous and anti-tuberculous
serotherapy.31 In fact, Landouzy refers implicitly to
differences in the use of statistics to define treatment
effectiveness by referring to the extent to which past
experience of the disease provided the basis for reli-
able inferences about the effects of treatments.
In the case of rabies and deadly venom inoculation,
the alternative facing physicians was to treat vic-
tims with inadequately tested treatments or to
watch them die. Unsurprisingly, all patients with
either of these two conditions were treated with vac-
cine or sera, with records only of the numbers of
survivors and deaths. The effectiveness of these treat-
ments was deduced from the divergence from expect-
ation of the cumulative ratio of survival to mortality,
with a discussion of possible explanations of the
failures.32
The success of serotherapy in tetanus was sporadic
and no statistical analysis was even attempted.
Landouzy refers to Marmorek’s clinical trials of an
anti-serum against streptococci, prepared in a similar
way to anti-diphtheria serum.33 Marmorek, who
worked under Roux’s supervision, compared the mor-
tality rate among all streptococcal infections in the
same hospital ward the year preceding the introduc-
tion of the anti-serum (5.12%) and during the year of
the trial (3.87%). Moreover, the serum was adminis-
tered only to patients with severe erysipelas. However,
no statistical protocol and no homogeneous cohort of
patients were defined. The statistics to which
Landouzy refers, thus appear quite primitive com-
pared with Roux’s studies of serum treatment of
diphtheria. This suggests that the evaluative methods
applied by Roux were not in common use at the
Institut Pasteur at that time.
Within a year of the report of Roux’s observations,
there were extensive data comparing the mortality of
treated cases with historical control data. In 1895, GC
Crandall reported that, having ‘recently had access to
the Library of the Royal College of Surgeons of
England, I gathered as fully as possible, statistics upon
the use of the anti-diphtheritic serum.’ He assembled
these data in what was essentially a systematic review,
which included 13 comparisons of treated cases to
historical controls (Table 1). Unfortunately, Crandall
did not provide references for these reports but in
some cases, at least there was consideration of the
appropriateness of different potential control data.
For example, in the report by Washbourn and his
colleagues,34 concurrent control data from other hos-
pitals—as used by Roux—were given. However, ‘on
account of the varying standards of diagnosis’,
Crandall decided not to lay much stress on these
data by comparison with the historical control data.
Further studies using observational
data and an abandoned
attempt to do a controlled
trial using alternation
The evidence from Paris and other evidence using his-
torical controls did not convince everyone of the value
of anti-diphtheritic serum, however. The debate was
complicated both because the disease was undergoing
spontaneous fluctuations with decreasing virulence
and by claims that the success of serum treatment
showed that laboratory research was a more promis-
ing approach to tackling diseases associated with pov-
erty than the social reforms for which Virchow and
others had been calling.35 Furthermore, deaths had
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been attributed to the anti-toxin, some of which at-
tracted wide publicity.31,35,36
Copenhagen was one of the places where doubts
about the claims made for serum therapy remained.
Sceptics emphasized the unpleasant effects of
serum therapy, and these meant that even doctors
who were themselves ill with diphtheria rejected the
therapy.37 Søren Thorvald Sørensen, professor at the
Blegdamshospitalet, conducted numerous investiga-
tions and remained unconvinced of the serum’s
assumed benefit and concerned about its adverse
effects.38–48
Sørensen conducted studies of anti-diphtheritic
serum at the Blegdamshospitalet, first using German
serum from October 1894 to February 1895,38–42,48
then French serum and Danish serum from March
1895 to March 1896.43–48
These studies attempted to evaluate the effects of
serum by selecting hospital patients who were as
comparable as possible with respect to age and symp-
toms but who had or had not been treated with
serum.37–48 The results of these comparisons using
observational data failed to identify convincing bene-
ficial effects of serum, possibly because patients who
were more sick had been selected for the serum
therapy.
Sørensen reported that 17 of 51 patients (33%) trea-
ted with German serum had died compared with
15 of 46 patients (33%) receiving no serum during the
same period. Of the patients who had received French
or Danish serum, 9 of 36 (23.8%) had died compared
with 5 of 19 patients (26.3%) who had not received
the serum during the same period. In both periods,
the decision to treat or not was by choice, albeit trying
to divide the patients to serum or no serum ‘as equal-
ly as possible’.46 Sørensen made clear that the slightly
lower estimate of mortality compared with untreated
controls in patients who had received French or
Danish serum should not be ascribed to the serum
used, but rather to the changing character of the epi-
demic. He appears to have been fully aware of the
fallacies of studies based on such observational data
for assessing the effects of interventions, mentioning
allocation biases and fluctuations in disease severity.
Accordingly, he went on to alternate patients to
receive or not receive serum:46
During the last months of the experimental phase
[with French and Danish serum, likely November
1895 to March 1896] we also tried to select every
second severe case for serum, but under the
available circumstances this method seemed less
Table 1 Statistics upon the use of the anti-diphtheritic serum, in Crandall (1895)
Number of
cases treated
with serum
Mortality
(%)
Previous
mortality
(%)
Vierordt Heidelberg 55 14.6 58.0
Ganghofner Prague 110 12.7 50.0
Wiederhofer Vienna 100 25.3 42.8
Kossel Berlin 350 16.7 34.7
Baginsky (quoted by Virchow) Berlin 303 3.2 47.8
Sonnenburg Berlin 107 20.6 27.6
Aronson Berlin 190 14.0 37.0
Ranke Munich 85 18.8 48.5
Saltmann Leipsic 122 18.0
Risel Halle 114 8.0
Roux, Martin and Chaillon Paris 300 26.0 51.7
Lebreton 258 12.0
Moizard Paris 231 14.7 50.0
Washbourn, Goodall, Card and others London 195 18.6 31.1
White New York 32 25.0 42.7
Withington Boston 80 16.0 45.0
Total number of cases 2632
Average mortality (%) 16.8
Previous average mortality (%) 42.9
Collective report of other observers in different countries 4022 17.1
Source: Crandall89
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successful. On the one hand, the method was dif-
ficult to carry out, and a subjective factor could
not be excluded; on the other hand, we obtained
only a few usable cases for our statistics, and the
cases seemed far more biased than the ones arbi-
trarily [Danish: vilka˚rlige] selected.
Owing to these problems, Sørensen abandoned his
attempt to do a controlled trial and did not report
separately the number of patients allocated by alter-
nation, nor their clinical results.46,48 Fibiger later
referred to these problems as ‘practical difficulties’.37
Sørensen’s conclusions after these studies were clear
and balanced. Although they provided no evidence
that serum therapy had had a beneficial effect on
either the course of the disease or the risk of death,
this absence of evidence could not be taken as evi-
dence that there was no beneficial effect: the experi-
ments had been too few in number; most patients
had been selected for serum treatment or no serum
treatment using subjective clinical assessment and the
number of deaths had been too few to provide reliable
statistics.37,48
Controlled trials to assess the
effects of serum treatment
of diphtheria
These uncertainties prompted Johannes Fibiger, pro-
fessor Sørensen’s junior colleague, to propose that
further, more rigorously controlled research was
needed.37 Professor Sørensen consented to Fibiger’s
plan, as long as Fibiger himself carried out the experi-
ment.37 Hro´bjartsson, Gøtzsche and Gluud have re-
ported elsewhere about what ensued.8
The introduction to Fibiger’s report explains why he
had remained unconvinced by the evidence provided
by Emile Roux and his colleagues.37 Fibiger acknow-
ledges that the comparison of serum-treated patients
with concurrent patients not-so-treated provided the
basis for a potentially dependable verdict on the ef-
fects of the serum. However, he was concerned that
the introduction of serum treatment at the Hoˆpital
des Enfants-Malades had coincided with improve-
ments in isolation routines and hygiene, so that ‘the
evidential weight of the experiments was lost’.
[Considering that Roux and his colleagues had ob-
tained their non-serum treated controls from another
hospital (the Hoˆpital Trousseau) Fibiger might also
have drawn attention to the fact that the Hoˆpital
Trousseau was located in a working-class area of
Paris; but he did not.]
Fibiger summarized a number of reports from the
USA, Germany, Norway and Denmark suggesting that
diphtheria had become less aggressive at the end of
the 19th century, as well as referring to Sørensen’s
unconvincing results.37 He concluded that ‘a new
series of experiments had to be planned, and planned
in such a way that the result would be absolutely
conclusive’.37
Fibiger’s introduction sets out the rationale for the
methodological features of his trial:
Even with minimal knowledge of diphtheria epi-
demics, one will recognise that it is necessary to
have (1) large numbers, and (2) a long study period.
To compensate for the large seasonal variation in
mortality, the study should last at least one year.
Truly, the control cases in the earlier studies were
selected to be as similar as possible to the ones
treated with serum, but to eliminate completely
the play of chance and the influence of subjective
judgement, one had to use a different procedure.
The only method that could be used rationally was
to treat every other patient with serum and every
other patient in the usual way.
In many cases a trustworthy verdict can only be
reached when a large number of randomly
[Danish: tilfældig] selected patients are treated
with the new remedy and, at the same time, an
equally large number of randomly [Danish:
tilfældig] selected patients are treated as usual.
The choice of Fibiger’s allocation method probably
reflects the earlier decision to abandon a trial in
which Sørensen had planned to allocate patients al-
ternately to receive or not to receive serum.43
Whatever the nature of the ‘practical reasons’ may
have been for abandoning this plan, Fibiger proposed
and Sørensen accepted that all patients admitted on
one day would be treated with serum but none would
be so treated the next day.37 As noted by Hro´bjartsson
and his colleagues, this arrangement left open the
possibility of allocation bias, since physicians could
favour the admission of the most severely affected
patients on the days that serum was being used.
Since Fibiger was also aware of the possibility of ob-
server bias in this unblinded trial, he tried to minim-
ize inter-observer variation by using ‘concordant
observations’ by the consultant and himself.
Between May 13, 1896 and May 13, 1897, 1004 pa-
tients were admitted to the Blegdamshospitalet with
presumed diphtheria. Fibiger excluded 520 of these
patients from the analysis, and gives a full account
of the reasons. Exclusions were mainly made because
the diagnosis had not been confirmed bacteriological-
ly (493 patients), but other patients were excluded
because they were moribund on admission or had
additional serious infections. The remaining 484 pa-
tients—all with bacteriologically confirmed diphtheria
and croup—were included in Fibiger’s analysis.
These arrangements led to a comparison of
well-matched groups of 239 patients who received
serum with 245 patients who did not. There were
eight deaths in the serum group (3%) and 30 deaths
in the control group (12%).4,37 Using terminology
which antedates its more specific meaning today,
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Fibiger concluded that ‘no objection can be raised
against the statistical significance of the numbers’,
which were deemed correct by an inspector from
the Sick Benefit Association.4,37 However, this benefi-
cial effect came at a cost: at least 145 out of the 239
patients (60%) who had been treated with serum de-
veloped serum sickness.
Alternate allocation trials and
uncertainty in America
It is notable that Sørensen’s and Fibiger’s studies
were conducted in the setting of scepticism surround-
ing the use of serum, as such scepticism also led to
a similar trial being carried out in America during
the latter half of the 1890s. William H Park (1863–
1939), who would go on to become the influential
director of the laboratories of the New York Board
of Health,49 was by the mid-1890s an early supporter
of diphtheria anti-toxin and Diphtheria Diagnostician
at the Willard Parker Hospital in New York City.
At the same hospital, attending physician Joseph E
Winters50,51 had become a very prominent and vocal
opponent of anti-toxin, first engaging with Park in
public debate before the New York Academy of
Medicine in April 1895. By May of 1896, Winters con-
cluded a long paper read before the New York
Academy of Medicine by saying that if he had
‘found that antitoxin did not do any harm, even
though it was valueless in the treatment of diphtheria
– even though it did not reduce the mortality – I
would never had said anything against it. It is be-
cause I believe it is dangerous that my convictions
compel me to speak. The time will come, gentlemen,
when every member of this academy will feel with
reference to it as I do tonight’.52
Describing this background 35 years later, Park
would relate his response to Winters’ claims:
An interesting experience developed in the Willard
Parker Hospital during the winter of 1896. One of
the leading paediatricians of the city and an at-
tending physician at the hospital was violently
opposed to the use of antitoxin, and so I arranged
that alternate patients should receive the anti-
toxin, and the remainder should not receive it.
The test lasted six weeks; several of the patients
who were given the antitoxin early did surprisingly
well, while several with similar cases who did not
receive antitoxin did badly. The difference in the
outcome of the cases was so great that we decided
to discontinue the observations. We believed that
although we had lost a few lives by it, we had
gained a certainty as to the value of antitoxin
which we would not otherwise have obtained,
and this enabled us to persuade the members of
the medical profession much more rapidly than if
we had not carried out the experiment.53
Yet, the actual sequence of Park’s reporting of the
study is perhaps instructive regarding the perceived
value and acceptance of such alternation of patients
in America at the time it was purportedly conducted.
Despite contributing frequent reports to the ‘Medical
Record’ and ‘Medical News’ during the latter half of
the 1890s, Park never reported the study in those
journals; nor did he report on the study in his reviews
of the treatment of diphtheria in Alfred L Loomis’
and William Gilman Thompson’s System of Practical
Medicine29 or Hobart Hare’s System of Practical
Therapeutics,54 despite his inclusion of ‘statistics’ for
the year 1896 in the latter report. Indeed, it seems
that the most influential clinical investigation in
favour of anti-toxin in America during the latter
half of the 1890s would be the 1896 collective inves-
tigation by the American Pediatric Society concerning
the use of anti-toxin in private practice, gathering and
collating case series mortality data from 613 different
physicians.51,55,56
Park seems to have first publicly described his alter-
nate allocation study at a ‘symposium on serum ther-
apy’ before the New York County Medical Association
in what appears to have been early 1900, where he
related:
A very interesting test of the value of antitoxin in
diphtheria . . . was tried a year ago last summer.
For 6 weeks only every alternate case received
antitoxin. Dr. Winters looked after the treatment
of those not receiving it, and Dr. Berg, I believe,
those receiving it. I carefully watched both series
of cases, and the difference was very marked in
favour of the antitoxin series. Even Dr. Winters
did not ask to have the test prolonged.57
Such a recounting would seem to place the trial in
the summer of 1898. Park did not cite Fibiger in his
1900 report, but by the time he delivered his 1906
Harvey Lecture, he related: ‘An absolutely ideal
method to show the influence of antitoxin is one
made by Fibinger [sic]. . . . In this, at the same time
every other case [sic] was treated with antitoxin. . . .
This method, however, for obvious reasons is not
available at this time. We once made a similar test
at the Willard Parker Hospital’.58 Park cited a 1904
German review paper59 as his source for the Fibiger
information; and by 1912, in a paper justifying the
use of animal experimentation, Park reported his
own study as having taken place in 1895.60
An anonymous report61 in the ‘Echoes and
News’ section of the April 1, 1899 edition of the
Medical News on ‘The chlorin treatment of diphtheria’
related:
The chlorin treatment of diphtheria has been sub-
mitted to a test experiment at the Willard Parker
Hospital, New York City, during the past six
weeks. Every alternate patient ill with diphtheria
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received the chlorin treatment and every alternate
one the antitoxin treatment. In connection with
the chlorin treatment tonics and general sustain-
ing remedies were used. Dr. Winters supervised
the chlorin treatment, and Dr. Berg the antitoxin.
The mortality was higher, and the patients gener-
ally seemed to be decidedly worse with the chlorin
treatment than those with the antitoxin. It is the
opinion of those who witnessed the results that
the chlorin solution seemed harmless, but useless.
It produced neither good nor bad results. The
course of the disease presented the picture so fa-
miliar previous to the discovery of antitoxin.
It is not clear whether the ‘chlorin’ experiment was
the original alternate allocation study later recounted
by Park, or whether it was a follow-up study. Park
may have conducted his original alternate allocation
study in 1895, 1896, 1898 or 1899. These multiple
cited dates may reflect simple misattribution, or pos-
sibly an attempt to establish precedence over Fibiger.
Indeed, it appears that the very idea of using alterna-
tion of patients may have come from Park’s sceptical
colleague Joseph Winters.62 For our purposes here,
however, what is most relevant is that Park’s appar-
ent reluctance to report the study before 1900 reveals
that the calculus concerning the merits and draw-
backs (from ethical to logistical) to the method-
ology—especially when compared with the
methodology of ‘collective investigation’—was not as
unequivocably favourable at the time as it would
become in retrospect.
Park would become increasingly familiar and com-
fortable with alternate allocation studies. In his 1906
Harvey Lecture, he referred to a recent compilation of
findings from alternate allocation studies of serum
therapy for plague carried out in India, which he
may have encountered in the Indian plague commis-
sion report,63 although no citation is given. By the
1920s, Park would play a key role in advancing the
use of alternate allocation in the evaluation of
anti-pneumococcal anti-serum,64–66 while also appar-
ently using the method to test the utility of scarlet
fever anti-toxin in 1925.67 His halting reporting of the
use of alternation thus lends important nuance to the
emergence of what must have seemed a powerful, yet
in certain ways, problematic methodology during this
time.
A controlled trial to evaluate ways
of reducing the adverse reactions
to anti-diphtheritic serum
Reactions to serum, some of them fatal,68 were a sig-
nificant problem, and ways of reducing them were
explored. In 1896, Almroth Wright69 had proposed
that calcium chloride might reduce urticaria and
other reactions to sera, and his findings were
replicated in Paris in 1904 by Arnold Netter. Netter’s
doctoral student—Maurice Cousin—conducted a well
controlled clinical trial to assess the value of prophy-
lactic calcium chloride in patients admitted to the
Diphtheria Pavilion of the Hoˆpital Trousseau.70,71
Cousin’s doctoral thesis described the procedure
adopted (Box 2) and the rationale for and execution
of alternate allocation to avoid allocation bias was
summarized by Arnold Netter the following year:71
To reassure ourselves of the value of this treatment
and to eliminate all risks of error, we used the
method of alternation [la me´thode alternante] . . .
Only the order of admission of the children deter-
mined their assignment to one or to the other
category.
Box 2 Extract from Maurice Cousin’s doctoral
thesis (Source: Cousin69)
A. METHOD OF ADMINISTRATION OF
CALCIUM CHLORIDE. MODE OF
COMPARISON
We have seen, in the previous chapter, which
eruptions have been very variable, depending
on the serum used. They can also depend, to a
certain extent, on the severity of the diphtheria.
To make sure to eliminate causes of error in
comparing results obtained with and without
calcium chloride, this is how M. NETTER
decided to proceed:
The children were divided into two categories:
even numbers and uneven numbers. These
numbers represented, not the numbers of
their beds, but the order in which they were
admitted to the Diphtheria Pavilion, as from
January 1905.
The twenty first child to be admitted, for ex-
ample, having this number based on [his]
order in the admission register, will be
added to the uneven numbers, however ser-
ious his disease. The one who is admitted
after him, the twenty second therefore, will
be placed among the even numbers, regard-
less of any other consideration.
In this way, two series of children will be
obtained: in one as in the other one will
find mild cases and severe cases, vigorous
children and frail children, etc.
Furthermore, children joining one or other
series on the same day are inoculated with
the same serum, and this exposed to exactly
the same risks. In a word, the conditions are
absolutely the same.
These two categories once assembled, the
one, the even series, will receive calcium
chloride, the other, the uneven series, does
not receive it.’
670 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Of 516 children admitted between 15 January and
31 December 1905 to the diphtheria pavilion at the
Trousseau Hospital who received injections of
anti-diphtheria serum, 258 thus received calcium
chlorate; 258 serving as controls did not receive
this treatment.
The Cousin/Netter controlled trial demonstrated that
fewer children (12/258) who had been allocated cal-
cium chloride experienced serum reactions than the
control children (41/264).
A similar study done at the Wilhelmina Hospital in
Amsterdam and referring to the Cousin/Netter con-
trolled trial was reported 2 years later by Dr J Gewin:
Of the 200 patients who were all treated (injected
with) Spronck‘s anti-diphtheria serum, one half
(even numbers) received calcium, the other half
(uneven numbers) [did] not [receive it], without
considering gender, age or [the severity of] the
throat affection. As much as possible the children
were given in the same order the serum which was
given on that same date [day]; thereby we wanted
to achieve that the children of one of the two
groups (categories) did not receive per chance a
very poisonous serum . . . Approximately half of
the children in each age group received calcium
chloride, the other half not.71
Blinded, controlled comparisons of
different anti-diphtheritic sera
With the uptake of serum treatment for diphtheria
from the end of the 19th century onwards, deaths
from the disease fell dramatically,3 albeit less dramat-
ically in countries, such as the UK, in which serum
treatment had not been adopted wholeheartedly.35
Nevertheless, although there was wide-spread accept-
ance that anti-diphtheritic serum was effective, the
orthodox explanation of its mechanism of action
was challenged by the results of further clinical
trials done by Adolph Bingel (1879–1953), head of
internal medicine (1910–48) at the City General
Hospital in Brunswick (Germany).73,74
Bingel was an original and extremely methodical
thinker and practitioner. In 1921, he reported on his
first 40 cases of pneumo-encephalography, a proced-
ure he had co-invented; and 2 years later he pub-
lished the results of his first 100 liver biopsies. It is
not clear what stimulated his interest in the serum
treatment of diphtheria, but this interest endured
during the rest of his career.75
The accepted account of the serum’s mechanism of
action was that specific anti-toxins produced by arti-
ficially infected animals neutralized toxins released by
diphtheria bacteria in infected humans (measured
using a method developed by Ehrlich to measure
the anti-toxin content of the blood serum). The
development and testing of this theory in animals
had led to the award of the first Nobel Prize in physi-
ology or medicine, in 1901, to Behring. Acceptance of
the theory had been reflected in the establishment of se-
rum factories all over the Western world, using horses
(for quantitative reasons) as ‘anti-toxin producers’.
Bingel, however, was sceptical of the orthodox view
that these specific ‘healing-sera’ were responsible for
the serum’s anti-diphtheritic effects.73 During a severe
epidemic in the winter of 1910–11, variable responses
to the anti-toxin serum had prompted him to wonder
whether its beneficial effect was solely due to the
anti-toxin. Might it not be caused by non-specific
action resulting simply from administering a serum
from another species to patients? Bingel was aware
of ‘the enormous influences of (foreign) protein
from strange (non-human) species’, as manifested
in serum disease and its marked effects on haemato-
logical indices. He was at pains to emphasize that he
had not the slightest intention of casting doubts on
the results of animal research on immunity, but noted
that the variable clinical picture of human diphtheria,
‘with its numerous and diverse complications’, was
completely different from the ‘experimentally induced
infection or intoxication of an animal’, so ‘whether a
drug influences a human disease can only be decided
in man’. This reasoning of species-specific pathophysi-
ology and therapy were the basis for Bingel’s decision
to undertake a trial comparing (Behring’s) ‘anti-toxin
serum’ with ‘normal serum’, that is, serum derived
from horses that had not been infected with diph-
theria: ‘If no differences are found, the anti-toxin
cannot be the effective agent’.73
Given the widely acknowledged effectiveness of
Behring’s anti-toxin serum, Bingel proceeded cau-
tiously, using alternation to create comparable
groups of patients:
After I had treated some adult diphtheria patients
with ordinary horse serum in 1911, I began in 1912
to treat alternate adult patients with antitoxin serum
and with ordinary serum, exactly in the temporal
sequence in which they were admitted to the
ward. The children all received antitoxin serum.
In the second half of the year 1912 and in the
first half of 1913, I gradually lowered the age of
those to be treated with ordinary horse serum, and
from 1 July 1913 [till 31st December 1916 when
he stopped the trial], every second case was trea-
ted with ordinary horse serum, whether child or
adult, regardless of the severity of the illness or
the presence of complications.
Bingel noted that:
. . . it is absolutely inadmissible to compare the re-
sults for different time periods, for example to give
antitoxin serum during one year, and then to give
only ordinary horse serum during a second year,
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and then to compare the results. That would lead
to seriously wrong conclusions, for in no infectious
disease is the nature of the epidemic so changeable
as in diphtheria. Mostly we see light epidemics,
but quite serious ones still occur. I remind [the
reader] of the heavy epidemics in Berlin and
Hamburg of the year 1910, and the one in
Leipzig of 1914, which recall the bad times of
the period before serum.73
In addition to using alternation to address this prob-
lem, Bingel also took steps to reduce observer biases.
He noted that it was ‘extraordinary difficult . . . to
evaluate the influences of therapy on disease unless
they are obvious, as for example, the success of a
surgical operation or cure of syphilis with mercury
or Salvarsan. The therapeutic optimist very easily
sees improvement, and the sceptic sees nothing’. In
order to reduce these problems, Bingel concealed the
identity of the two sera from his assistants and
nurses, using the cover names of ‘old serum’ (for
the antitoxin serum) and ‘new serum’ or ‘red
serum’ (for normal serum).
To make the trial as objective as possible, I have
not relied on my own judgment alone, but have
sought the views of the assistant physicians of the
diphtheria ward, without informing them about
the nature of the serum under test (namely the
ordinary horse serum). Their judgement was thus
completely without prejudice. I am keen to see my
observations checked independently, and most
warmly recommend this ‘blind’ method for the
purpose. Even the chief physician may try to
draw conclusions about the nature of the
serum (unknown to him) that has been used in
a particular case: he will be astonished to see how
little he is able to do this . . . .Neither I nor my as-
sistants Dr Reusz, Dr Schwab, Dr Weber, Dr Lube
could detect a difference between the two sera.
Dr Koennecke thought the old (antitoxin) serum
had a certain advantage, while Dr Rehder declared
that if he were to fall ill, he would wish to be
treated with the new (horse) serum. The views
of these two gentlemen thus neutralised each
other.73
Although Bingel did not mention ‘blinding’ the pa-
tients participating in his trial, it is clear from the
context that it was a blinded trial in which patients,
caregivers and observers were blinded to the interven-
tion, and he recommended that others should use
blinding in replications of his study.73
Bingel insisted on using measurable criteria ‘in order
to achieve an objective overall assessment’, which he
contrasted with ‘impressions’ from the bedside. His
final report was based on an analysis of 471 patients
treated with anti-toxin serum and 466 with normal
serum.73 The results were meticulously analysed and
presented in detailed tables, as well as in diagrams
and illustrative case reports. No marked differences
were detected between the impacts of the two sera
on the time to shedding of the diphtheritic mem-
branes, or on mortality: there were 47 deaths out of
471 patients (10.0%) given anti-toxin serum, com-
pared with 49 deaths out of 466 patients (10.5%)
given normal serum. Nor were differences detected
in subgroup analyses in patients who had had tra-
cheotomies or other complications, or after consider-
ing the sources of their infections (e.g. from within
families). Bingel was also aware of the need to study
large numbers of patients to reduce the effects of
chance, and claimed that his sample had been ‘suffi-
ciently large to prove that no preference can be
claimed for anti-toxin serum’.73
Bingel’s challenging results provoked strong and
often emotional reactions, which were reported in
the lay press. After all, an achievement crowned
with a Nobel Prize, and thus the prestige of German
basic research, was at stake. In general, the paper was
simply dismissed. In a response,76 Bingel pointed out
that he had never contested either the therapeutic or
the prophylactic value of Behring’s anti-toxin serum.
He acknowledged a valid criticism that the normal
serum might have contained some anti-toxin, and
admitted that such a possibility had not occurred to
him as he assumed that what he had bought
from industry labelled as ‘normal horse serum’ was
what had been advertised. To address the criticism, he
commissioned analyses of samples of the normal
serum he had used. These did indeed reveal a
very low concentration of anti-toxin in some of the
samples tested—1–3 international units per cubic
centimetre. Bingel deemed this to be so low that it
could not have had any material effect when com-
pared with an anti-toxin concentration of 500 inter-
national units per cubic centimetre, with patients
receiving an average total dose of between 2000 and
8000 international units.76 This argument prompted
some of Bingel’s critics to admit that anti-toxin
serum must contain other unspecified therapeutic
elements besides the anti-toxin, but it did not stop
the defenders of anti-toxin serum continuing to dis-
miss his provocative findings. As Bingel pointed out
later,77 their views implied that 1–3 international
units of serum were as effective as 500 U. He was
also criticized for withholding from patients a
proven effective therapy in order to test a patho-
physiological hypothesis. In response, he asserted
that the final decision about the therapeutic value
in man of a drug stemming from animal experiments,
however well justified theoretically, remained
with clinicians and that it was also the clinicians’
business, and not that of serologists, whether such
studies were to be regarded as consistent with med-
ical ethics.77
Bingel’s defence was clearly persuasive to some clin-
icians, however, and his request that his trial be
672 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
replicated was taken up by some other researchers.
Hottinger and Toepfer,78 for example, reported four
separate trials, the largest of which alternated 400
patients to either anti-toxin serum or normal serum.
Like Bingel, they were unable to detect any differen-
tial effects of the two sera. In the 1940s, Bingel him-
self performed two further large trials comparing
anti-toxin serum and normal serum.74,75 After he
had analysed the cases assembled in his three com-
parative trials, he concluded that anti-toxin was not
the active agent in serum therapy of human diph-
theria; the sera acted non-specifically ‘as a stimulant
activating the defence forces [of the body]’. As in his
1918 trial, Bingel allocated patients in his two later
trials to anti-toxin or normal serum using alternation,
a method to which he now sought to give credibility
by referring to Paul Martini’s78 support of the ap-
proach: ‘With this ‘‘alternating method’’ I believe I
would achieve statistically irreproachable [einwandfrei]
results (see Martini)’.76
Adolph Bingel’s writings in 1918, and subsequently,
reveal considerable methodological and epistemologic-
al sophistication. His application, a century ago, of a
controlled, double-blind clinical trial involving sub-
stantial numbers of patients demonstrates the sophis-
tication developed in the study of therapeutic
innovations, years before the advent of formal
randomization.
The need for international
comparative research on the
evolution of methods for
testing treatments
In this article, we have used examples selected from
the development of treatments for diphtheria to illus-
trate the development of methods for unbiased as-
sessments of the effects of treatments. Our examples
have illustrated the use of case reports and case series
to demonstrate dramatic effects of treatment; histor-
ical controls and concurrent (non-randomized) con-
trols to assess measures to reduce cross-infection
and the effects of anti-toxin serum; alternation to
control allocation bias in evaluating the effects of
anti-toxin sera, treatments for adverse reactions to
serum and the relative merits of different sera;
double blinding to control observer biases and recog-
nition of the need for large numbers of observations—
all by 1918.
The examples we have cited make clear that at least
some researchers in France, Denmark, Germany and
the USA were espousing principles and applying
methods at the beginning of the 20th century that
would eventually lead, during the second half of the
century, to the emergence of the controlled clinical
trial as we know it today. With some important ex-
ceptions, most existing histories of clinical trials have
focused on the use of random allocation to generate
treatment comparison groups, thus generally ignoring
the prior history of alternation to create comparison
groups during the first half of the 20th century.80 The
use of alternation ‘to avoid the imputation of selec-
tion’ in generating treatment comparison groups
began at least as early as the middle of the 19th cen-
tury81 and possibly earlier,82 and not only in Europe
and North America, but also, for example, in the
Malay States.83,84 India was the location of a particu-
larly large number of such alternate allocation studies
from the late 19th century onwards, for cholera and
plague vaccines and plague serum therapy. The latter
is represented by NH Choksy’s report85 reprinted in
the current issue of the IJE, with the commentaries
on it providing details regarding the extraordinary
flurry of related activity at this time in India.86–88
Emerging resources, including full text-searchable
journals, are now enabling more extended research
into the development of such methods as some
among many for promoting ‘rational’ therapeutics at
the end of the 19th and beginning of the 20th
centuries.56,89
There is also a noticeable lack of documentation
and analysis of the evolution of controlled trials in
countries other than Britain and the USA.90–94 We
hope that this ‘taster’ of other material that awaits
discovery, documentation and analysis may help
to stimulate research into the evolution of con-
trolled clinical trials in countries other than Britain
and the USA. As Ilana Lo¨wy95 has observed, ‘trans-
national comparisons may display unexpected differ-
ences and/or surprising similarities; questions initially
studied in one context can acquire a different mean-
ing when transposed to another situation; a juxta-
position of developments in several sites can
provide information impossible to obtain in single-
site studies’.
The kind of international approach we believe is
needed is illustrated in Kaptchuk’s history of blind
assessment and placebo controls;96 indeed, it was
Kaptchuk who drew our attention to Adolf Bingel’s
remarkable 1918 study. Additional comparative inter-
national analyses of the evolution of research meth-
ods for testing treatments during the first half of the
20th century would help to provide the background
against which a broad international consensus about
research methods emerged during the second half of
the century.
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